Ivan Kairatov stands at the crossroads of a historic transformation in medicine, having spent years navigating the high-stakes world of biopharmaceutical research and development. As an expert with deep roots in both the technical and innovative corridors of the industry, he has witnessed the slow, meticulous transition of longevity science from a niche academic pursuit into a robust, multi-billion-dollar therapeutic sector. His perspective is grounded in the reality of clinical pipelines and the shifting priorities of global healthcare leaders who are now viewing aging not as an inevitability, but as a biological process that can be targeted and treated. In this conversation, we explore the significance of the upcoming 13th Aging Research & Drug Discovery (ARDD) meeting at Harvard and how the convergence of AI, big pharma, and institutional investment is finally moving cellular rejuvenation and longevity medicine into the mainstream.
Our discussion delves into the strategic relocation of the world’s largest longevity conference to Boston, signaling the field’s entry into the global epicenter of biomedical innovation. We also examine the massive momentum generated by recent clinical successes, the critical role of artificial intelligence in shortening drug discovery timelines, and the diverse ecosystem of sponsors—from tech-driven biotech startups to legacy financial institutions—that are now backing these ambitious programs.
Boston has emerged as the global epicenter for biomedical innovation as longevity science moves from theoretical concepts to multi-billion-dollar therapeutic pipelines. What does hosting the world’s largest conference on longevity biotechnology at Harvard University signify for the field’s maturity?
The move to the David Rubenstein Treehouse at Harvard University for the 13th ARDD Meeting in October 2026 is a watershed moment that signifies the end of the “fringe” era for longevity science. When you see a landmark event officially organized by a pioneer like Insilico Medicine and anchored by a global giant like Eli Lilly, you realize we are no longer just talking about mice in lab basements; we are talking about the high-profile launch of Boston Longevity Week. This transition into the very heart of the world’s most dense biomedical ecosystem reflects a paradigm shift where aging research is now recognized as a core pillar of healthcare. There is a palpable sense of gravity when you gather the brightest minds at Harvard to discuss multi-billion-dollar therapeutic pipelines that were once considered science fiction. It tells the world that the science is ready for the rigors of mainstream clinical research and the scrutiny of big pharma’s executive leadership.
Following the momentum from the 2025 meeting in Copenhagen, how has the involvement of pharmaceutical giants like Eli Lilly and Novo Nordisk redefined the commercial landscape for longevity-focused therapies?
The momentum from Copenhagen was truly transformative, particularly when leadership from Eli Lilly and Novo Nordisk began openly discussing the profound longevity potential of GLP-1 receptor agonists in publications like Nature Biotechnology. This isn’t just a trend; it’s a fundamental restructuring of how top-tier pharmaceutical companies view their commercial programs. We are now seeing these companies actively develop and scale programs targeting a broad spectrum of age-related conditions, including fibrosis, immunology, CNS disorders, and anti-muscle wasting. The presence of executive leaders from 10 of the world’s top pharmaceutical companies at the upcoming conference proves that the “longevity dividend” is a serious financial and clinical target. By integrating longevity into their portfolios, these firms are essentially betting that cellular rejuvenation and metabolic health will be the next great frontier in global health economics.
The ARDD 2026 program features a dedicated track for AI in Drug Discovery. In your experience, how is artificial intelligence specifically accelerating the journey from basic aging research to actual clinical trials?
Artificial intelligence is the engine driving the “AI in Drug Discovery Track” on October 2nd, and its impact is most visible in how it compresses the traditionally decade-long timeline of drug development. In my research, I’ve seen how AI platforms, like those pioneered by Insilico Medicine, can identify novel targets for complex diseases and design molecular structures with a precision that human researchers alone could never achieve. It allows us to sift through mountains of basic science data to find the specific pathways involved in cellular aging and prioritize the ones most likely to succeed in human trials. This reduces the “valley of death” between the lab and the clinic, making it much more attractive for institutional investors to step in. When you have elite chairs from Harvard Medical School and the University of Copenhagen guiding these AI tracks, you are ensuring that the technology is tethered to the highest standards of scientific evidence.
With specialized days focusing on Clinical Development and Future Technology, how essential is this multidisciplinary approach for navigating the regulatory and technical hurdles of longevity medicine?
A multidisciplinary approach is the only way to navigate the “Longevity Medicine Track” and the subsequent “Future Technology Track” because the hurdles we face are as much regulatory as they are biological. On October 1st, the focus on clinical development is crucial because we need to define clear endpoints for aging-related trials that the FDA and other bodies can approve. Then, by October 3rd, shifting to future technology allows us to look at the next wave of innovation, such as cellular rejuvenation and advanced biomarkers. This structure ensures that we aren’t just innovating in a vacuum; we are building a bridge between the academic insights of people like Vadim Gladyshev and the commercial reality of sponsors like AbbVie or BioAge. It creates a space where a scientist from the National University of Singapore can sit down with a venture capitalist to discuss the actual mechanics of bringing a drug to market.
The roster of sponsors for 2026 includes not just biotech firms like Human Longevity and BioAge, but also financial institutions like Morgan Stanley and McKinsey Health Institute. What does this diverse backing tell us about the long-term economic forecast for the longevity sector?
The inclusion of McKinsey Health Institute as the Sole Knowledge Partner, alongside financial heavyweights like Morgan Stanley and Synaro Capital, indicates that the world’s most influential decision-makers now view longevity as a primary driver of future economic growth. We are seeing a diverse array of backing from Tier 3 sponsors like Tally Health, Maxwell Biosciences, and TruDiagnostic, which shows that the ecosystem is becoming incredibly specialized and robust. When you have Tier 5 support from entities like Healthy Longevity and QuadraScope, it suggests a healthy appetite for risk-managed investment across the entire spectrum of the industry. This isn’t just about selling a product; it’s about a wholesale transformation of health economics where the goal is to extend the period of life spent in good health. The financial sector is clearly betting that the companies solving these fundamental biological challenges will be the most valuable entities of the next decade.
What is your forecast for longevity biotechnology over the next five years as these theoretical pipelines begin to yield results?
I forecast that within the next five years, we will see the first true “longevity drugs”—therapies originally developed for specific diseases but proven to have systemic anti-aging effects—become standard of care for at-risk populations. The transition from Copenhagen to Boston is just the beginning of a massive clinical surge where the 10 top pharmaceutical companies currently involved will likely double their investment in cellular rejuvenation programs. We will see a shift in the regulatory landscape where “biological age” becomes a recognized and actionable metric in clinical settings, supported by the diagnostic tools currently being refined by companies like TruDiagnostic and Cyclarity Therapeutics. Ultimately, the “longevity medicine” we discuss today at Harvard will simply become known as “preventative medicine” tomorrow, as we move away from treating symptoms of decay and toward preserving the integrity of the human body at a cellular level. It is a future where the multi-billion-dollar pipelines we see today result in a global decrease in the burden of age-related disease, fundamentally changing what it means to grow old.
